GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Voyager Therapeutics Inc (STU:VT6) » Definitions » Cyclically Adjusted FCF per Share

Voyager Therapeutics (STU:VT6) Cyclically Adjusted FCF per Share : €-0.28 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Voyager Therapeutics Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Voyager Therapeutics's adjusted free cash flow per share for the three months ended in Mar. 2024 was €0.912. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-0.28 for the trailing ten years ended in Mar. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2024-06-25), Voyager Therapeutics's current stock price is €7.49. Voyager Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was €-0.28. Voyager Therapeutics's Cyclically Adjusted Price-to-FCF of today is .

During the past 11 years, the highest Cyclically Adjusted Price-to-FCF of Voyager Therapeutics was 119.78. The lowest was 77.33. And the median was 84.62.


Voyager Therapeutics Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Voyager Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Voyager Therapeutics Cyclically Adjusted FCF per Share Chart

Voyager Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -0.39

Voyager Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -0.39 -0.28

Competitive Comparison of Voyager Therapeutics's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Voyager Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Voyager Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Voyager Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Voyager Therapeutics's Cyclically Adjusted Price-to-FCF falls into.



Voyager Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Voyager Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.912/131.7762*131.7762
=0.912

Current CPI (Mar. 2024) = 131.7762.

Voyager Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 4.047 99.621 5.353
201506 -0.453 100.684 -0.593
201509 -0.243 100.392 -0.319
201512 -0.356 99.792 -0.470
201603 -0.356 100.470 -0.467
201606 -0.350 101.688 -0.454
201609 -0.375 101.861 -0.485
201612 -0.630 101.863 -0.815
201703 -0.625 102.862 -0.801
201706 -0.576 103.349 -0.734
201709 -0.523 104.136 -0.662
201712 -0.432 104.011 -0.547
201803 1.200 105.290 1.502
201806 -0.638 106.317 -0.791
201809 -0.492 106.507 -0.609
201812 -0.676 105.998 -0.840
201903 3.292 107.251 4.045
201906 -0.784 108.070 -0.956
201909 -0.562 108.329 -0.684
201912 -0.653 108.420 -0.794
202003 -0.742 108.902 -0.898
202006 -0.554 108.767 -0.671
202009 -0.674 109.815 -0.809
202012 -0.563 109.897 -0.675
202103 -0.485 111.754 -0.572
202106 -0.507 114.631 -0.583
202109 -0.481 115.734 -0.548
202112 0.254 117.630 0.285
202203 0.821 121.301 0.892
202206 -0.487 125.017 -0.513
202209 -0.421 125.227 -0.443
202212 -0.323 125.222 -0.340
202303 2.726 127.348 2.821
202306 -0.043 128.729 -0.044
202309 -0.466 129.860 -0.473
202312 -0.446 129.419 -0.454
202403 0.912 131.776 0.912

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Voyager Therapeutics  (STU:VT6) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

During the past 11 years, the highest Cyclically Adjusted Price-to-FCF of Voyager Therapeutics was 119.78. The lowest was 77.33. And the median was 84.62.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Voyager Therapeutics Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Voyager Therapeutics's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Voyager Therapeutics (STU:VT6) Business Description

Industry
Traded in Other Exchanges
Address
64 Sidney Street, Cambridge, MA, USA, 02139
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. The company operates in a single segment of developing and commercializing gene therapies.

Voyager Therapeutics (STU:VT6) Headlines

No Headlines